

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

SCHEDULE 13G
Under the Securities and Exchange Act of 1934
(Amendment #1)

Akoya Biosciences, Inc.

(Name of Issuer)

Common Stock, par value \$0.00001 per share

(Title of Class of Securities)

00974H104

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1 (b)
 Rule 13d-1 (c)
 Rule 13d-1 (d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)

CUSIP NO. 00974H104 13G

1 Name of Reporting Person
PSC Capital Partners LLC

2 Check the Appropriate Box if a Member of a Group (a)
(b)

3 SEC Use Only

4 Citizenship or Place of Organization
Delaware

Number of Shares	5	Sole Voting Power 2,717,360 shares
Beneficially Owned By	6	Shared Voting Power 0 Shares
Each Reporting Person	7	Sole Dispositive Power 2,717,360 shares
With	8	Shared Dispositive Power 0 Shares

9 Aggregate Amount Beneficially Owned by Each Reporting Person
2,717,360 Shares

10 Check if the Aggregate Amount in Row (9) Excludes Certain
Shares

11 Percent of Class Represented by Amount in Row (9)
7.2%

12 Type of Reporting Person
IA

CUSIP NO. 00974H104 13G

1 Name of Reporting Person
Piper Sandler Companies

2 Check the Appropriate Box if a Member of a Group (a)
(b)

3 SEC Use Only

4 Citizenship or Place of Organization
Delaware

Number of
Shares 5 Sole Voting Power
185 shares

Beneficially
Owned By 6 Shared Voting Power
19,616 Shares

Each
Reporting Person 7 Sole Dispositive Power
185 shares

With 8 Shared Dispositive Power
19,616 Shares

9 Aggregate Amount Beneficially Owned by Each Reporting Person
19,801 Shares

10 Check if the Aggregate Amount in Row (9) Excludes Certain
Shares [X]

11 Percent of Class Represented by Amount in Row (9)
Less than 1%

12 Type of Reporting Person
HC

CUSIP NO. 00974H104 13G

1 Name of Reporting Person
PJC Capital LLC

2 Check the Appropriate Box if a Member of a Group (a) []
(b) [X]

3 SEC Use Only

4 Citizenship or Place of Organization
Delaware

Number of
Shares 5 Sole Voting Power
0 shares

Beneficially
Owned By 6 Shared Voting Power
19,616 Shares

Each
Reporting Person 7 Sole Dispositive Power
0 shares

With 8 Shared Dispositive Power
19,616 Shares

9 Aggregate Amount Beneficially Owned by Each Reporting Person
19,616 Shares

10 Check if the Aggregate Amount in Row (9) Excludes Certain
Shares [X]

11 Percent of Class Represented by Amount in Row (9)
Less than 1%

12 Type of Reporting Person
HC

Item 1 (a) Name of Issuer: Akoya Biosciences, Inc.

Item 1 (b) Address of Issuer Principal Executive Offices:

100 Campus Drive, 6th Floor,
Marlborough, MA 01752

Item 2 (a) Name of Persons Filing:

This Schedule 13G is being filed jointly by the entities identified below (collectively, the Reporting Persons):
* PSC Capital Partners LLC
* Piper Sandler Companies
* PJC Capital LLC

Item 2 (b) Address of Principal Business Office:

800 Nicollet Mall Suite 900
Minneapolis, MN 55402 - for all Reporting Persons

Item 2 (c) Citizenship:

U.S. (Delaware) - For all Reporting Persons

Item 2 (d) Title of Class of Securities: Common Stock, par value \$0.00001 per share

Item 2 (e) CUSIP Number: 00974H104

Item 3 If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c) of the Securities Exchange Act of 1934 as amended (the "Exchange

- (a) Broker or dealer registered under Section 15 of the Exchange Act;
- (b) Bank as defined in Section 3(a)(19) of the Exchange Act;
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act;
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- (j) A non-US institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
- (k) A Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(ii)(J), please specify the type of institution.

Item 4 Ownership

- (a) through (c)

The information in Items 1 and 5 through 11 on the cover pages to this Schedule 13G are hereby incorporated by reference. Piper Sandler Companies is the Partners LLC). As to Piper Sandler Companies and PSC Capital Partners LLC, this Schedule 13G reflects a disaggregation of beneficial ownership between the

This Schedule 13G is not an admission that any of Reporting Persons are the beneficial owner of the securities covered by this report, except as ex

Item 5 Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

Not applicable.

Item 8 Identification and Classification of Members of the Group:

Not applicable.

Item 9 Notice of Dissolution of the Group:

Not applicable.

Item 10 Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purposes or effect.

List of Exhibits

Exhibit 99.1 Joint Filing Agreement - filed herewith

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PSC CAPITAL PARTNERS LLC

Date: 2/14/23

By /s/ Theodore J. Christianson

Signature

Name/Title Theodore J. Christianson, CEO

PIPER SANDLER COMPANIES

Date: 2/14/23

By /s/ Timothy L. Carter

Signature

Name/Title Timothy L. Carter, CFO

PJC CAPITAL LLC

Date: 2/14/23

By /s/ Timothy L. Carter

Signature

Name/Title Timothy L. Carter, CFO